CAR T-cell-associated neurotoxicity: A comprehensive review

Area of Science:

• Oncology
• Immunotherapy
• Neuroscience

Background:

• Chimeric antigen receptor T-cell (CAR T-cell) therapy is a novel immunotherapy for malignancies.
• CAR T-cell therapy demonstrates significant efficacy in hematological malignancies.
• Neurological complications are a known adverse event associated with CAR T-cell therapy.

Purpose of the Study:

• To review the neurological adverse events in patients receiving CAR T-cell therapy.
• To summarize the incidence, clinical presentations, and mechanisms of these neurological toxicities.
• To discuss potential strategies for managing CAR T-cell therapy-induced neurological adverse events.

Main Methods:

• Literature review of studies reporting neurological adverse events post-CAR T-cell therapy.
• Analysis of incidence rates and clinical manifestations.
• Synthesis of proposed underlying mechanisms and management approaches.

Main Results:

• CAR T-cell therapy is linked to a range of neurological adverse events.
• These events vary in severity and presentation.
• Understanding mechanisms is crucial for effective management.

Conclusions:

• Neurological adverse events are a critical consideration in CAR T-cell therapy.
• Further research into mechanisms and standardized management is needed.
• Proactive monitoring and intervention can improve patient outcomes.